Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 4 Next >
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Granted Key NASH Patent in Israel
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Issues Letter to Shareholders
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.